The current financial score of Jazz Pharmaceuticals PLC is 8.92. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 1.21B, representing a year-over-year increase of 15.55%, while its net profit experienced a year-over-year increase of 126.83%.
The current valuation score of Jazz Pharmaceuticals PLC is 9.45. Its current P/E ratio is 584.06, which is 8.63% below the recent high of 634.48 and 117.28% above the recent low of -100.94.
The current earnings forecast score of Jazz Pharmaceuticals PLC is 8.40. The average price target is 289.98, with a high of 337.00 and a low of 198.67.
The current price momentum score of Jazz Pharmaceuticals PLC is 3.21. Currently, the stock price is trading between the resistance level at 259.47 and the support level at 229.09, making it suitable for range-bound swing trading.
The current institutional shareholding score of Jazz Pharmaceuticals PLC is 10.00. The latest institutional shareholding proportion is 112.06%, representing a quarter-over-quarter increase of 8.45%.
The current risk assessment score of Jazz Pharmaceuticals PLC is 8.31. The company's beta value is 0.32. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.